Maxim Group Increases Sonoma Pharmaceuticals, Inc. (SNOA) Price Target to $9.00

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) had its price target lifted by stock analysts at Maxim Group to $9.00 in a report released on Friday. Maxim Group’s price objective would indicate a potential upside of 23.80% from the company’s previous close.

Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) opened at 7.27 on Friday. Sonoma Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $7.36. The company has a market cap of $30.95 million, a price-to-earnings ratio of 3.35 and a beta of 1.71. The stock has a 50 day moving average of $5.66 and a 200 day moving average of $4.67.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Thursday, February 9th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.08 by $0.76. Sonoma Pharmaceuticals had a negative return on equity of 82.81% and a net margin of 59.43%. On average, equities research analysts expect that Sonoma Pharmaceuticals will post $2.09 EPS for the current year.

This piece was reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this piece can be accessed at

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

5 Day Chart for NASDAQ:SNOA

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *